Rationale and Design of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) — Mihai Gheorghiade (2005) | RDL Network
Rationale and Design of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
Mihai Gheorghiade, Mazen Albaghdadi, Faı̈ez Zannad, Gregg C. Fonarow, Michael Böhm, Claudio Gimpelewicz, Jaco Botha, Shelley L. Moores, Eldrin F. Lewis, Henning Rattunde, Aldo Maggioni
Timothy Brighton, Amit Khot, Simon J. Harrison, David Ghez, Brendan M. Weiss, A. Kirsch, Hila Magen, Mercedes Gironella, Albert Oriol, Matthew Streetly, Britte Kranenburg, Xiang Qin, Rajesh Bandekar, Peter Hu, Mary Guilfoyle, Ming Qi, Sepideh Nemat, Hartmut Goldschmidt
Paul J. Hauptman, John C. Burnett, Mihai Gheorghiade, Liliana Grinfeld, Marvin A. Konstam, Dušan Kostić, Holly B. Krasa, Aldo Maggioni, John Ouyang, Karl Swedberg, Faı̈ez Zannad, Chris Zimmer, James E. Udelson
Richard K. Root, Robert F. Lodato, Ward Patrick, J. F. Cade, Nick Fotheringham, Steven Milwee, Jean Louis Vincent, Antoní Torres, Jordi Rello, Steve Nelson
Discussion(0)
No comments yet. Be the first to comment.